Loop Capital Upgrades Charter Communications (CHTR) Stock to Buy, Lifts PT
On May 19, Loop Capital Markets upped the rating on Charter Communications, Inc. (NASDAQ:CHTR)'s stock from 'Hold' to 'Buy,' raising the PT to $510 from the previous target of $430. The upgrade comes off the back of positive expectations for the company's growth after its proposed merger with Cox Communications.
As per the firm, the deal is expected to be anticipated to be beneficial, providing accretive value to Charter Communications, Inc. (NASDAQ:CHTR). It can also help reduce leverage and provide scale efficiencies, which can develop the company as the pre-eminent cable operator in the US.
A close up of a satellite in space, showing the advanced technology of communications systems.
The firm's analyst, Alan Gould, also noted the promising early results of Charter Communications, Inc. (NASDAQ:CHTR)'s 'Life Unlimited' rebrand. The analyst opines that the initiative provides a combined broadband and mobile service and also consists of customer service guarantees. The new video strategy offers customers access to an ad-supported tier of several streaming apps. This is given at no additional cost and can help offset the loss of video subscribers, says the analyst.
Overall, the proposed merger can create a more formidable entity in the broader telecommunications industry with the help of combining Charter Communications, Inc. (NASDAQ:CHTR)'s and Cox's resources.
While we acknowledge the potential of CHTR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CHTR and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: and 11 Unstoppable Growth Stocks to Invest in Now
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Jim Cramer on Build-A-Bear Workshop (BBW): 'I'm a Holder, Not a Buyer'
We recently published a list of . In this article, we are going to take a look at where Build-A-Bear Workshop, Inc. (NYSE:BBW) stands against other stocks that Jim Cramer discussed recently. A caller asked if they should hold, trim, or add to their position in Build-A-Bear Workshop, Inc. (NYSE:BBW). Cramer replied: 'Alright, I remember many, many years ago when Danny Meyer came here… and he said, listen, this is a company to watch. It is a company that is also a great hospitality company. And I'm going to tell you I have followed it ever since. I cannot believe it had that earnings breakout. And if anything… I'm a holder, not a buyer, because it just had that spike. But if it came down, I would certainly be a buyer.' A smiling woman walking out of a franchised store, her new purchase in her arm. Build-A-Bear Workshop (NYSE:BBW) is a retailer that provides customizable plush toys, pre-stuffed animals, scents, sounds, and a variety of accessories, clothing, and novelty items, with stores operating under the Build-A-Bear Workshop name. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
FTSE 100 LIVE: Stocks rise as traders await ECB interest rate decision
The FTSE 100 (^FTSE) and European stocks rose on Thursday as traders awaited the latest decision on interest rates from the European Central Bank (ECB). Interest rates across the eurozone are likely to be cut by 0.25% again today, as the bank attempts to support the euro economy after the turmoil caused by US president Donald Trump's trade wars. It will be the eighth cut in a year. It comes after eurozone inflation dropped to 1.9% last month, falling below the ECB's 2% target for the first time since last September. Markets are pricing almost a 100% probability of a quarter-point cut, according to Ronald Temple, chief market strategist at Lazard Asset Management. He said: "With ongoing declines in inflation and consistently dovish language from ECB members, a rate cut appears to be a done deal. The ECB has previously described 1.75%–2.25% as the range that would be considered neutral monetary policy. Any signals of a change in this view would be surprising. "I continue to expect rates to be reduced to 1.5% by year end given a more aggressive US trade posture against the European Union. Markets suggest a slightly less dovish outlook with rates ending the year just below 1.6%.' Investors will also focus on the ECB's latest forecasts at the scheduled press conference this afternoon. London's benchmark index (^FTSE) was hovering near the flatline in early trade. Germany's DAX (^GDAXI) rose just 0.2% and the CAC (^FCHI) in Paris also headed 0.2% into the green. The pan-European STOXX 600 (^STOXX) was up 0.2%. Wall Street is set for a positive start as S&P 500 futures (ES=F), Dow futures (YM=F) and Nasdaq futures (NQ=F) were all in the green. The pound was 0.1% up against the US dollar (GBPUSD=X) at 1.3564. Follow along for live updates throughout the day: Stocks in Asia were mixed overnight with the Nikkei (^N225) down 0.5% on the day in Japan, while the Hang Seng (^HSI) rose 0.9% in Hong Kong. The Shanghai Composite ( was 0.2% up by the end of the session. Across the pond on Wall Street, the S&P 500 (^GSPC) eked out a 0.01% gain, and the tech-heavy Nasdaq (^IXIC) was 0.3% higher. The Dow Jones (^DJI) lost 0.2% by the closing bell. Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets today, as well as all that's happening across the global economy. The main highlight of the day will be the ECB's latest policy decision and president Lagarde's subsequent press conference. Otherwise, we'll hear from the Fed's Kugler, Harker and Schmid, BoE deputy governor Breeden, and the BoE's Greene. Data releases from the US include the weekly initial jobless claims and the April trade balance. Meanwhile in Europe, there's German factory orders for April, and the May construction PMIs for Germany and the UK. Here's a quick snapshot of what's on the agenda for today: 7am: Trading updates: Mitie, Wizz Air, Workspace, Dr Martens, Young's & Co Brewery 7am: German factory orders for April 9am: UK new car sales report for May 9.30am: UK construction PMI report 1.15pm: European Central Bank interest rate decision 1.30pm: US trade data for April 1.30pm: US weekly jobless claims data 1.45pm: European Central Bank press conferenceStocks in Asia were mixed overnight with the Nikkei (^N225) down 0.5% on the day in Japan, while the Hang Seng (^HSI) rose 0.9% in Hong Kong. The Shanghai Composite ( was 0.2% up by the end of the session. Across the pond on Wall Street, the S&P 500 (^GSPC) eked out a 0.01% gain, and the tech-heavy Nasdaq (^IXIC) was 0.3% higher. The Dow Jones (^DJI) lost 0.2% by the closing bell. Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets today, as well as all that's happening across the global economy. The main highlight of the day will be the ECB's latest policy decision and president Lagarde's subsequent press conference. Otherwise, we'll hear from the Fed's Kugler, Harker and Schmid, BoE deputy governor Breeden, and the BoE's Greene. Data releases from the US include the weekly initial jobless claims and the April trade balance. Meanwhile in Europe, there's German factory orders for April, and the May construction PMIs for Germany and the UK. Here's a quick snapshot of what's on the agenda for today: 7am: Trading updates: Mitie, Wizz Air, Workspace, Dr Martens, Young's & Co Brewery 7am: German factory orders for April 9am: UK new car sales report for May 9.30am: UK construction PMI report 1.15pm: European Central Bank interest rate decision 1.30pm: US trade data for April 1.30pm: US weekly jobless claims data 1.45pm: European Central Bank press conference
Yahoo
44 minutes ago
- Yahoo
Oculis Publishes Results of 2025 Annual General Meeting
ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ('Oculis' or the 'Company'), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The Company's shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory financial statement basis, the Company incurred a loss of CHF 5,179,000 with respect to the financial year ended December 31, 2024, and resolved that the accumulated balance sheet loss of CHF 46,577,000 shall be carried forward to the new accounts. The members of the Board of Directors and the Executive Committee were granted discharge for their activities in 2024. Anthony Rosenberg was re-elected as member and chairperson of the Board of Directors. Christina Ackermann, Lionel Carnot, Arshad M. Khanani, Martijn Kleijwegt, Geraldine O'Keeffe, Riad Sherif and Robert K. Warner were re-elected as members of the Board of Directors. Christina Ackermann, Lionel Carnot and Robert K. Warner were re-elected as members of the Compensation Committee. PricewaterhouseCoopers SA (Pully) was re-elected as Statutory Auditors. PST Legal AG (Zug) was re-elected as Independent Proxy. The shareholders approved the compensation for the non-executive members of the Board of Directors: Total maximum amount of fixed (non-performance-related) compensation for the non-executive members of the Board of Directors until the end of the Company's 2026 Annual General Meeting: USD 572,000. Maximum value of equity or equity-based compensation for eight non-executive members of the Board of Directors until the end of the Company's 2026 Annual General Meeting: USD 2,150,000 (excluding employer social security and pension contributions). The shareholders approved the compensation for members of the Executive Committee: Total maximum amount of fixed (non-performance-related) compensation for three members of the Executive Committee for the calendar year 2026 and payable in 2026: USD 2,478,240. Total maximum amount of variable compensation for three members of the Executive Committee for the calendar year 2025 and payable in 2026 of USD 1,753,760. Maximum value of equity-based compensation for three members of the Executive Committee until the end of the calendar year 2026: USD 15,500,000 (excluding employer social security and pension contributions). The shareholders approved, in a non-binding advisory vote, the 2024 Compensation Report of the Company. The shareholders approved a capital band of 27,266,837 registered shares resulting in a capital band between CHF 545,336.74 and CHF 818,005.11 and the related amendment of the paragraphs 1 through 3 of article 3a of the articles of association in the form published on the website of the Company at The shareholders approved a conditional share capital for employees and individuals of comparable positions in the maximum amount of CHF 124,800 by the issuance of 12,480,000 registered shares and the related amendment of article 3c, paragraph 1 of the articles of association in the form published on the website of the Company at About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS / XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis' highly differentiated pipeline of multiple innovative product candidates in clinical development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: Oculis Contacts Ms. Sylvia Cheung, CFO Investor Relations LifeSci Advisors Corey Davis, Ph.D. cdavis@ Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous oculis@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
